Alps Group’s MyGenome Gains MS ISO 15189:2022 Approval for Whole Genome Sequencing
ALPS•Alps Group subsidiary MyGenome earned MS ISO 15189:2022 accreditation for Whole Genome Sequencing, joining a select group of Southeast Asian labs with WGS under these clinical standards. This validation enhances data accuracy and reliability benchmarks, opening markets in government-linked healthcare, cross-border partnerships, and institutional research across the region.
1. Accreditation Achievement
MyGenome Sdn. Bhd., a subsidiary of Alps Group Inc, has secured MS ISO 15189:2022 accreditation for its Whole Genome Sequencing process, placing it among a limited number of Southeast Asian laboratories operating under this clinical standard.
2. Technical Standards and Quality
The accreditation verifies that MyGenome’s WGS meets stringent accuracy, reproducibility, and reliability benchmarks required for clinical and research applications, distinguishing it from targeted genetic panels by analyzing the patient’s complete DNA sequence.
3. Expanded Market Opportunities
This clinical-grade credential enables Alps to pursue government-linked healthcare programs, cross-border partnerships, and institutional clients across Southeast Asia, strengthening its positioning in precision medicine and genomics research collaborations.
